The estimated Net Worth of Herm Cukier is at least $737 Tausend dollars as of 4 May 2020. Herm Cukier owns over 66,666 units of Biodelivery Sciences International stock worth over $572,679 and over the last 7 years Herm sold BDSI stock worth over $164,346.
Herm has made over 3 trades of the Biodelivery Sciences International stock since 2019, according to the Form 4 filled with the SEC. Most recently Herm exercised 66,666 units of BDSI stock worth $372,663 on 4 May 2020.
The largest trade Herm's ever made was exercising 66,666 units of Biodelivery Sciences International stock on 4 May 2020 worth over $372,663. On average, Herm trades about 19,568 units every 22 days since 2018. As of 4 May 2020 Herm still owns at least 102,447 units of Biodelivery Sciences International stock.
You can see the complete history of Herm Cukier stock trades at the bottom of the page.
Herm's mailing address filed with the SEC is 4131 Parklake Ave #225, Raleigh, NC 27612, USA.
Over the last 21 years, insiders at Biodelivery Sciences International have traded over $111,671,776 worth of Biodelivery Sciences International stock and bought 1,813,177 units worth $5,352,510 . The most active insiders traders include International, L.P. Elliott, Associates, L.P. Elliott und Healthcare Master Fund Ltd .... On average, Biodelivery Sciences International executives and independent directors trade stock every 18 days with the average trade being worth of $420,648. The most recent stock trade was executed by Jeffrey Allen Bailey on 9 March 2022, trading 5,333 units of BDSI stock currently worth $29,811.
BioDelivery Sciences International, Inc. is a commercial-stage specialty pharmaceutical company dedicated to patients living with chronic conditions. BDSI has built a portfolio of products that includes utilizing its novel and proprietary BioErodible MucoAdhesive (BEMA®) technology to develop and commercialize, either on its own or in partnership with third parties, new applications of proven therapies aimed at addressing important unmet medical needs. BDSI's marketed products address serious and debilitating conditions, including chronic pain and opioid-induced constipation.
Biodelivery Sciences International executives and other stock owners filed with the SEC include: